Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial

Abstract Background Previous studies evaluating antiangiogenic agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma (HCC) have shown encouraging results. This study was conducted to investigate the efficacy and safety of donafenib combined with sintilimab (Don-Sin) for...

Full description

Bibliographic Details
Main Authors: Xiaoyang Hong, Yongjian Guo, Wenbo Shi, Kangshun Zhu, Licong Liang, Liteng Lin, Ye Chen, Jingwen Zhou, Jingjun Huang, Jiabai Huang, Yaozhu Wu, Wensou Huang, Mingyue Cai
Format: Article
Language:English
Published: BMC 2025-02-01
Series:BMC Cancer
Subjects:
Hepatocellular carcinoma
Tyrosine-kinase inhibitor
Donafenib
Immune-checkpoint inhibitor
Programmed death 1 inhibitor
Sintilimab
Online Access:https://doi.org/10.1186/s12885-025-13605-2

Internet

https://doi.org/10.1186/s12885-025-13605-2

Similar Items